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Abstract 1 
Background: Smoking is not associated with prostate cancer incidence in most 2 
studies, but associations between smoking and fatal prostate cancer have been 3 
reported. 4 
Methods: During 1992 and 2000, lifestyle information was assessed via 5 
questionnaires and personal interview in a cohort of 145,112 European men. Until 6 
2009, 4623 incident cases of prostate cancer were identified, including 1517 cases of 7 
low-grade, 396 cases of high-grade, 1516 cases of localized, 808 cases of advanced 8 
disease, and 432 fatal cases. Multivariable Cox proportional hazards regression 9 
models were used to examine the association of smoking status, smoking intensity, 10 
and smoking duration with the risk of incident and fatal prostate cancer. 11 
Results: Compared with never smokers, current smokers had a reduced risk of 12 
prostate cancer (RR=0.90, 95% CI 0.83-0.97), which was statistically significant for 13 
localized and low-grade disease, but not for advanced or high-grade disease. In 14 
contrast, heavy smokers (25+ cigarettes/day) and men who had smoked for a long 15 
time (40+ years) had a higher risk of prostate cancer death (RR=1.81, 95% CI 1.11-16 
2.93; RR=1.38, 95% CI 1.01-1. 87, respectively).  17 
Conclusion: The observation of an increased prostate cancer mortality among heavy 18 
smokers comfirms the results of previous prospective studies. 19 
 20 
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 4 
Introduction 1 
Prostate cancer is the most common incident cancer in males in developed 2 
countries (Ferlay et al, 2004). Due to the large international variation in prostate 3 
cancer incidence and mortality rates, lifestyle is hypothesized to play a significant 4 
role inprostate cancer development, though the precise etiologic factors have not 5 
been identified Cigarette smoking is still common in Europe, with up to 40% of the 6 
adult male population smoking in 2008 (European Health for All statistical database: 7 
http://www.who.dk/). Smoking is a well-known risk factor for several cancers, its 8 
relationship with prostate cancer risk is less clear. In a recent meta-analysis, current 9 
smoking was not associated with risk of prostate cancer, but there was an increased 10 
risk among heavy smokers (Huncharek et al, 2010). However, in that study, current 11 
smoking was associated with increased prostate cancer mortality (Huncharek et al, 12 
2010) and a recent study showed that smoking at the time of diagnosis was related 13 
to a higher risk of prostate cancer-specific mortality (Gong et al, 2008).  14 
To broaden our knowledge on the association of smoking with prostate cancer 15 
incidence and mortality, we investigated prospectively the association between 16 
cigarette smoking and prostate cancer incidence and mortality in the European 17 
Prospective Investigation into Cancer and Nutrition (EPIC). 18 
 19 
Material and Methods 20 
 21 
Study Population 22 
EPIC is a large prospective cohort study conducted in 23 centers in 10 23 
European countries [Denmark (Aarhus, Copenhagen), France, Germany 24 
(Heidelberg, Potsdam), UK (Cambridge, Oxford), Greece, Italy (Florence, Naples, 25 
Ragusa , Turin, Varese), The Netherlands (Bilthoven, Utrecht), Norway, Spain 26 
 5 
(Asturias, Granada, Murcia, Navarra, San Sebastian), Sweden (Malmö, Umea)] 1 
including more than 500,000 participants. The details of the recruitment process 2 
have been described previously (Riboli et al, 2002). In brief, in most centers, the 3 
participants were recruited from the general population. Italian and Spanish 4 
participants were recruited among blood donors, members of several health 5 
insurance programs, employees of several enterprises, civil servants, but also the 6 
general population. In Oxford, half of the cohort consisted of ‘health conscious’ 7 
subjects from across the UK. The cohorts of France, Naples, Norway, and Utrecht 8 
included women only (Riboli et al, 2002). All subjects gave written informed consent 9 
to use their questionnaire data and the Internal Review Boards (IRB) of the 10 
International Agency for Research on Cancer (IARC) and all EPIC recruitment 11 
centers approved the analyses based on EPIC participants. 12 
Of the 148,016 men without prevalent cancers (other than non-melanoma skin 13 
cancer) eligible for analysis, men with incomplete follow-up and missing information 14 
on smoking status were excluded, leaving 145,112 men available for analysis. 15 
 16 
Exposure assessment 17 
At study recruitment, detailed information was assessed on lifetime history of 18 
consumption of tobacco products. This included questions on smoking status 19 
(current, past, or never smoker), number of cigarettes currently smoked, average 20 
number of cigarettes smoked over their lifetime, the age when participants started 21 
and, if applicable, quit smoking. 22 
Diet over the previous twelve months was assessed using dietary assessment 23 
instruments that were specifically developed for each participating country (Riboli et 24 
al, 2002). Baseline intake of energy and nutrients was calculated from the dietary 25 
instruments applied in each center (Riboli et al, 2002). Detailed information was also 26 
 6 
assessed on leisure-time, occupational, and household physical activity as well as 1 
education and marital status. Comparability of non-dietary questions was ensured by 2 
a set of core questions that were similar in all participating centers (Riboli et al, 3 
2002). Height and weight were measured in all EPIC centers except for Oxford, 4 
where self-reported height and weight measurements were available (Riboli et al, 5 
2002).  6 
 7 
Outcome assessment 8 
 Cancer diagnoses were based on population registries in Denmark, Italy, the 9 
Netherlands, Spain, Sweden, and UK. An active follow-up through study subjects 10 
and next-of-kin information, the use of health insurance records, and cancer and 11 
pathology registries were used in Germany and Greece. Mortality data were obtained 12 
from either the cancer or mortality registries at the regional or national level. Cancer 13 
cases were identified by the end of the censoring periods ending between December 14 
2004 and December 2008, depending on the most recent comparison of a center’s 15 
database with the respective cancer registry. For Germany and Greece, the end of 16 
the follow-up was the last known contact, date of diagnosis, or date of death, 17 
whichever came first. 18 
 Definition of prostate cancer cases were based on the 10th revision of the 19 
International Classification of Diseases (ICD-10) and included all invasive malignant 20 
neoplasms, coded as C61. Information on tumor TNM stage and histological grade 21 
was collected from each center, where possible. Of 4623 incident prostate cancer 22 
cases, information was available on stage for 50% and on grade for 41%. Tumors 23 
were classified as localized (T0/T1/T2 and N0/NX and M0, or stage coded in the 24 
recruitment center as localized; n=1516) or advanced (T3 or T4 and/or N1+ and/or 25 
M1, or stage coded in the recruitment center as advanced or metastatic; n=808). 26 
 7 
Also, tumors were divided into low histological-grade (Gleason score 2-7 or 1 
equivalent [cases coded as well or moderately differentiated]; n=1517) or high-grade 2 
(Gleason score ≥ 8 or equivalent [cases coded as poorly differentiated or 3 
undifferentiated]; n=396). During the follow-up period, 432 fatal cases of prostate 4 
cancer were identified. 5 
 6 
Statistical analysis 7 
Cox proportional hazards regression was used to examine the association of 8 
smoking status at recruitment, smoking intensity (cigarettes/day in current smokers; 9 
mean lifetime number of cigarettes/day in former smokers), duration of smoking, and 10 
time since quit smoking. All analyses were conducted separately for former and 11 
current smokers. Smoking status was defined as never, former, current smokers; 12 
duration of smoking as < 10, 10-19, 20-29, 30-39, and 40+ years; time since quit 13 
smoking as < 5, 5-9, 10-19, and 20+ years ago; and number of cigarettes smoked 14 
per day as 1-14, 15-24, and 25+. Age was the primary time metric in the Cox 15 
proportional hazards models. Time at study entry was age at baseline, exit time was 16 
age when participants were diagnosed with cancer, died, were lost to follow-up, or 17 
were censored at the end of the follow-up period, whichever came first. Exit time for 18 
the analysis of prostate cancer mortality was age when participants died, were lost to 19 
follow-up, or were censored at the end of the follow-up period, respectively. The 20 
analyses were stratified by center and age at recruitment in one-year categories. 21 
Multivariate models were adjusted for body weight and height at recruitment (as 22 
continuous variables), marital status (single/divorced/widowed, married/living 23 
together, missing), education (primary school or less, technical/professional school, 24 
secondary school, university, missing), and vigorous physical activity (none, ≤ 2 25 
hours/week, >2 hours/week, missing). Models that included additional adjustments 26 
 8 
for intake of energy, alcohol, red meat, processed meat, tomato sauce, vitamin E, 1 
and calcium did not materially alter the results and are not presented here. We also 2 
simultaneously adjusted for smoking intesity and duration, which, however, did not 3 
materially change the observed associations. Tests for trend were conducted using 4 
integer scores for categories of smoking intensity, smoking duration, and years since 5 
quit smoking. Sub-analyses were performed by stage and grade of prostate cancer, 6 
by age at recruitment(<60, ≥ 60), and by BMI (<25, ≥ 25 kg/m2). We tested for 7 
interaction of age and BMI with smoking status in prostate cancer risk by including 8 
cross-product terms along with the main effect terms in the Cox regression model. 9 
The statistical significance of the cross-product terms was evaluated using the 10 
likelihood ratio test. We tested for heterogeneity by outcome strata (i.e., low-grade 11 
vs. high-grade tumors; localized vs. advanced tumors) using the data augmentation 12 
method by Lunn and McNeil (Lunn & McNeil, 1995). Heterogeneity between 13 
countries was assessed using likelihood chi-square tests. All analyses were 14 
conducted using SAS version 9.1 (SAS Institute, Cary, North Carolina). 15 
 16 
Results 17 
Median follow-up time of the cohort was 11.9 (interquartile range 10.6-13.1) 18 
years. Former smokers were older and had a higher BMI than never and current 19 
smokers (Table 1). Current smokers had a higher intake of total energy, alcohol and 20 
red meat than never and former smokers and were more often physically inactive. 21 
Fomer smokers were more often married or lived together with a partner. Never 22 
smokers more often had a university degree than former and current smokers. 23 
Current smokers had a significantly lower risk of prostate cancer than never 24 
smokers (RR=0.90, 95% CI 0.83-0.97; Table 2). This inverse association was 25 
evident for localized (RR=0.86, 95% CI 0.75-0.99) and low-grade disease (RR=0.83, 26 
 9 
95% CI 0.72-0.95), but not for advanced (RR=1.05, 95% CI 0.87-1.27) and high-1 
grade disease (RR=1.13, 95% CI 0.86-1.47).  2 
Among former and current smokers, smoking intensity and smoking duration 3 
were weakly inversely associated with prostate cancer, with similar associations 4 
observed for localised and low-grade disease (Table 2). No associations were 5 
observed for advanced or high-grade disease. Former smokers who had smoked for 6 
at least 40 years had an increased risk of advanced prostate cancer compared with 7 
never smokers (RR=1.45, 95% CI 1.05-2.00). Also, men who had recently, i.e., < 5 8 
years before recruitment, quit smoking had a non-significantly higher risk of 9 
advanced disease than never smokers (RR=1.32, 95% CI 0.98-1.76), but the tests 10 
for trend were not statistically significant. No such associations were observed for 11 
high-grade disease (Table 2). Simultaneously adjusting dose for duration did not 12 
materially alter the observed associations (data not shown). 13 
Current smoking was associated with a non-significant increased risk of 14 
prostate cancer mortality compared with never smokers (RR=1.27, 95% CI 0.98-15 
1.65). In particular, a high intensity of smoking (RR=1.81, 95% CI 1.11-2.93, 25+ 16 
cigarettes/day vs. non-smokers) and a long duration of smoking (RR=1.38, 95% CI 17 
1.01-1.87, 40+ years vs. non-smokers) were associated with a statistically 18 
significantly increased risk of prostate cancer death (Table 2). In a joint-effects 19 
analysis, we combined smoking status and smoking intensity (Figure 1) clearly 20 
showing an association between heavy current smoking and prostate cancer 21 
mortality, but no association for former smokers. 22 
In a sub-analysis, we examine whether the categorization of tumors with 23 
Gleason sum of 7 into the group of high-grade cancer or as a separate group 24 
changed our results. For current smokers, the RR was 0.79 (95% CI 0.68-0.93) for 25 
tumors with Gleason sum < 7 and 1.03 (95% CI 0.85-1.26) for tumors with Gleason 26 
 10 
sum 7+. Using 3 groups for Gleason sum, the results were as follows: Gleason sum 1 
< 7: RR=0.79 (95% CI 0.68-0.93); Gleason sum = 7: RR=0.94 (95% CI 0.71-1.25); 2 
and Gleason sum 8+ RR=1.13 (95% CI 0.86-1.47). 3 
We examined whether the associations between current smoking and prostate 4 
cancer incidence and mortality differed by country, but did not detect statistically 5 
significant heterogeneity (all p-values > 0.05). Also, results did not differ by BMI or 6 
age group (p-values for interaction > 0.05). 7 
 8 
Discussion 9 
In this European cohort study, smoking was associated with a small reduction 10 
in the risk of prostate cancer, which was significant for less aggressive disease; there 11 
was no association between smoking and more aggressive incident disease. 12 
Smoking, in particular heavy smoking, was associated with a significant increase in 13 
risk of death from prostate cancer. 14 
To date, most studies have not observed significant associations of smoking 15 
with overall prostate cancer incidence (Hickey et al, 2001; Huncharek et al, 2010). In 16 
the current study, we found that men who were smokers at recruitment had a 10% 17 
lower risk of prostate cancer overall than never smokers, whereas no significant 18 
association was seen for former smokers. However, the inverse association of 19 
current smoking with prostate cancer risk was confined to localized and low-grade 20 
disease. Similar inverse associations between smoking and low-grade prostate 21 
cancer have been reported in other studies (Giovannucci et al, 2007), (Watters et al, 22 
2009). It is possible that this association may reflect a detection bias, such that 23 
smokers are less likely to seek medical attention and undergo medical tests and 24 
therefore are less likely to be diagnosed with non-aggressive prostate cancer, or 25 
equally likely non-smokers may be more inclined to seek medical attention and be 26 
 11 
diagnosed with non-aggressive prostate cancer. We do not have information on 1 
prostate cancer testing in this study population and, thus, cannot evaluate the 2 
associations stratified by screening behavior. However, in the NIH-AARP cohort, the 3 
inverse association between smoking and non-advanced prostate cancer was 4 
observed among men who had undergone DRE and PSA testing within the past 3 5 
years and was, thus, independent of such screening (Giovannucci et al, 2007; 6 
Watters et al, 2009). The authors of that study speculated an inverse association 7 
between smoking and prostate cancer incidence might partly be explained by effects 8 
of smoking on circulating levels if insulin-like growth factor-I and sex hormone 9 
binding globulin (Giovannucci et al, 2007; Watters et al, 2009). However, further 10 
research is needed to clarify the true association between smoking and non-11 
aggressive prostate cancer. 12 
 13 
Heavy smokers had an increased risk of dying from prostate cancer, which is 14 
consistent with findings from previous US studies (Batty et al, 2008; Coughlin et al, 15 
1996; Giovannucci et al, 2007; Giovannucci et al, 1999; Hsing et al, 1991; Hsing et 16 
al, 1990; Rodriguez et al, 1997; Rohrmann et al, 2007; Watters et al, 2009; 17 
Weinmann et al, 2010). Zu & Giovannucci (Zu & Giovannucci, 2009) concluded that, 18 
compared to never smokers, current smoking is associated with an increased risk of 19 
about 30% for fatal prostate cancer; depending on the comparison, the increase in 20 
risk ranges from 14% to 30% in the meta-analysis of Huncharek et al. (Huncharek et 21 
al, 2010). These estimates are similar to our estimate of a 27% higher risk of fatal 22 
prostate cancer comparing current with never smokers. An aggressive phenotype of 23 
prostate cancer may develop in smokers, for example due to mutations in genes 24 
such as p53 (Giovannucci et al, 1999). Continued exposure of the nascent prostate 25 
tumor to carcinogens present in cigarette smoke and the loss of glutathione S-26 
 12 
transferase pi in prostate cancers (Lin et al, 2001), which metabolizes and inactivates 1 
a number of carcinogens, might promote tumor progression (Roberts et al, 2003). 2 
Increased oxidative stress may promote an accumulation of somatic mutations in 3 
cancer cells and smoking-induced inflammation could also contribute to tumor 4 
progression (Gong et al, 2008). Two recent US studies have shown that men who 5 
smoked at diagnosis were more likely to progress (Joshu et al, 2011) and to die from 6 
the disease (Kenfield et al, 2011), but another study did not find an association of 7 
smoking with biochemical recurrence of the tumor (Moreira et al, 2010). However, all 8 
of these hypotheses implicate an effect of smoking via disease progression. For this 9 
to be true, one would also expect an association of heavy smoking with advanced 10 
disease. However, our findings do not support the hypothesis of an association 11 
between smoking and advanced or high-grade disease. 12 
In our analysis, we were able to take into account several potential 13 
confounders of the association between cigarette smoking and prostate cancer risk, 14 
i.e., body height and weight, education, marital status, energy intake, and vigorous 15 
physical activity. The follow-up period in EPIC is relatively short (median of 11.9 16 
years) compared with other cohort studies. However, this is not necessarily a 17 
disadvantage because some studies have shown that there seems to be a 18 
relationship between recent smoking and prostate cancer risk. A study by Hsing et al 19 
with 26 years of follow-up observed an attenuation of the association between 20 
smoking and prostate cancer mortality with increasing follow-up time (Hsing et al, 21 
1991). Similarly, an association between cigarette smoking and prostate cancer 22 
mortality was seen in the first 10 years of follow-up in a US cohort study but not when 23 
considering total follow-up time (Rohrmann et al, 2007). When relying on a man’s 24 
smoking status as reported at baseline, it is likely that there is less misclassification 25 
of smoking status earlier in follow-up than later in follow-up, when men may have 26 
 13 
subsequently quit smoking. A further limitation is possible misclassification of cause 1 
of death, i.e., men with prostate cancer did not actually die of prostate cancer but of 2 
co-morbidity, however, the cause of death was attributed to prostate cancer. We 3 
relied on the underlying cause of death on death certificates and did not verify cause 4 
of death from medical records. However, in the Health Professionals Follow-up 5 
Study, re-examination of medical records by blinded reviewers had shown that 6 
deaths attributed to prostate cancer were likely to be truly prostate cancer specific 7 
(Giovannucci et al, 1999). Also, we do not have systematic information on prostate 8 
cancer sreening behaviour across the cohorts. We cannot exclude that screening 9 
behaviour differs between countries and is associated with the prevalence of 10 
smoking. The prevalence of smoking varies between the participating centers and 11 
countries, with rates below 25% in Sweden and Germany (as well as the British 12 
health-conscious cohort) and more than 40% in Spain and Greece. Never-smoking 13 
rates ranged between 26% in Greece and 44% in Sweden. Thus, we cannot exclude 14 
that our results are affected by some residual confounding arising from differences in 15 
smoking prevalence and screening behaviour. Finally, we have conducted several 16 
sub-analyes and, thus, cannot exclude the some of our findings might be due to 17 
chance. 18 
In conclusion, smoking appears to be associated with a lower risk of less 19 
aggressive prostate cancer, whilst heavy smoking is associated with an increased 20 
risk of prostate cancer death. Future studies are warranted to examine whether these 21 
associations are due to different health-care seeking behavior between smokers and 22 
non-smokers, and whether stopping smoking at the time of prostate cancer diagnosis 23 
will decrease the risk of dying from this disease as well as many other diseases.24 
 14 
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Figure 1: Association of smoking intensity (cigarettes per day by smoking status) 
and (a) prostate cancer incidence and (b) prostate cancer mortality in EPIC 
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Table 1. Baseline characteristics of male EPIC participants by smoking status at 
baseline, 1992-2000 
 Never smokers Former smokers Current smokers 
 Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) 
Age at recruitment (years) 51.4 (42.6- 58.8) 54.8 (48.7- 61.1) 51.9 (45.1- 58.0) 
BMI (kg/m2) 25.7 (23.6- 28.1) 26.7 (24.6- 29.0) 26.0 (23.8- 28.5) 
Body height (cm) 175.3 (170.1-180.0) 174.5 (170.0-179.0) 174.3 (169.5-179.2) 
Marital status (%)*    
   Single 14.3 6.4 12.9 
   Married/living together 78.8 85.4 76.4 
   Divorced/separated 5.4 6.1 9.0 
   Widowed  1.4 2.1 1.6 
Vigorous  physical activity*    
   None 31.4 35.1 41.8 
   ≤ 2 hours/week 21.1 20.9 17.2 
   >2 hours/weeks 20.9 22.4 18.2 
Highest level of education (%)*    
   Primary school or less 25.8 31.5 36.6 
   Technical/prof. school 22.8 25.6 26.3 
   Secondary School 17.0 14.9 15.9 
   University degree 32.4 25.4 20.1 
*sum does not add up to 100% because of missing information 
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Table 2. Association of smoking with prostate cancer in EPIC 
Variable Total prostate cancer Localized cases Advanced cases Low-grade cases High-grade cases Prostate cancer death 
 
N HR* 95% CI N HR* 95% CI N HR* 95% CI N HR* 95% CI N HR* 95% CI N HR* 95% CI 
Smoking status                   
  Never smokers 1547 1.00 (reference) 531 1.00 (reference) 239 1.00 (reference) 585 1.00 (reference) 124 1.00 (reference) 128 1.00 (reference) 
  Former smoker 1996 0.96 (0.90, 1.03) 624 0.90 (0.80, 1.01) 353 1.02 (0.86, 1.20) 590 0.83 (0.74, 0.93) 166 0.99 (0.78, 1.25) 183 0.96 (0.76, 1.21) 
  Current smoker 1080 0.90 (0.83, 0.97) 361 0.86 (0.75, 0.99) 216 1.05 (0.87, 1.27) 342 0.83 (0.72, 0.95) 106 1.13 (0.86, 1.47) 121 1.27 (0.98, 1.65) 
p-heterogeneity    0.02 0.02    
         
Former smokers                   
Smoking intensity                  
  1-14 cig./day  658 0.96 (0.87, 1.06) 265 0.92 (0.79, 1.07) 157 1.08 (0.88, 1.33) 262 0.85 (0.73, 0.99) 75 1.05 (0.77, 1.41) 63 1.13 (0.81, 1.59) 
  15-24 cig./day 407 0.88 (0.78, 0.98) 187 0.98 (0.82, 1.16) 94 0.94 (0.74, 1.21) 156 0.75 (0.62, 0.90) 50 0.97 (0.69, 1.37) 34 0.85 (0.57, 1.28) 
  > 25 cig./day 134 0.88 (0.73, 1.06) 44 0.75 (0.55, 1.03) 32 0.96 (0.66, 1.41) 51 0.72 (0.54, 0.97) 18 0.97 (0.58, 1.62) 15 1.18 (0.67, 2.07) 
p-trend   0.02   0.18   0.74   0.0004   0.89   0.95 
p-heterogeneity    0.07 0.01    
Duration of smoking                
  ≤ 10 years 295 1.16 (1.02, 1.31) 96 1.12 (0.90, 1.40) 44 1.11 (0.80, 1.53) 98 1.05 (0.85, 1.31) 30 1.32 (0.88, 1.98) 17 0.83 (0.49, 1.40) 
  10-19 years 460 0.91 (0.82, 1.01) 136 0.82 (0.68, 1.00) 75 0.93 (0.71, 1.21) 147 0.81 (0.68, 0.98) 31 0.73 (0.49, 1.09) 28 0.72 (0.48, 1.09) 
  20-29 years 513 0.91 (0.83, 1.01) 155 0.85 (0.71, 1.02) 94 1.02 (0.80, 1.30) 155 0.76 (0.63, 0.91) 46 0.94 (0.66, 1.32) 37 0.83 (0.57, 1.20) 
  30-39 years 399 0.93 (0.83, 1.04) 146 1.01 (0.83, 1.21) 68 0.92 (0.70, 1.22) 116 0.77 (0.63, 0.94) 47 1.28 (0.90, 1.81) 50 1.25 (0.89, 1.75) 
  ≥ 40 years 217 1.04 (0.90, 1.21) 60 0.93 (0.70, 1.23) 50 1.45 (1.05, 2.00) 54 0.90 (0.67, 1.20) 8 0.64 (0.31, 1.33) 32 1.21 (0.81, 1.82) 
p-trend   0.13   0.23   0.44   0.0007   0.90   0.36 
p-heterogeneity    0.04 0.06    
Quit smoking                   
  < 5 years ago 259 0.95 (0.83, 1.09) 75 0.85 (0.66, 1.08) 58 1.32 (0.98, 1.76) 78 0.84 (0.66, 1.07) 21 0.95 (0.59, 1.52) 27 1.28 (0.84, 1.96) 
  5-9 years ago 254 1.00 (0.88, 1.15) 94 1.13 (0.90, 1.41) 42 1.00 (0.72, 1.39) 80 0.88 (0.69, 1.12) 30 1.39 (0.93, 2.10) 24 1.17 (0.75, 1.82) 
  10-19 years ago 530 0.92 (0.83, 1.02) 162 0.87 (0.72, 1.04) 84 0.89 (0.69, 1.14) 153 0.74 (0.62, 0.89) 43 0.87 (0.61, 1.24) 44 0.96 (0.67, 1.36) 
  ≥ 20 years ago 869 0.97 (0.89, 1.06) 268 0.91 (0.78, 1.06) 149 1.01 (0.82, 1.25) 264 0.86 (0.74, 1.00) 70 0.96 (0.71, 1.30) 72 0.80 (0.59, 1.08) 
p-trend   0.32   0.35   0.31   0.01   0.74   0.27 
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p-heterogeneity    0.05 0.14    
         
Current smokers                   
Smoking intensity                  
  1-14 cig./day  420 0.97 (0.87, 1.08) 144 0.93 (0.77, 1.13) 80 1.15 (0.88, 1.49) 145 0.88 (0.73, 1.06) 44 1.32 (0.93, 1.89) 40 1.19 (0.82, 1.73) 
  15-24 cig./day 365 0.90 (0.80, 1.01) 116 0.84 (0.68, 1.03) 76 1.08 (0.82, 1.41) 112 0.80 (0.65, 0.99) 32 1.10 (0.74, 1.65) 40 1.31 (0.90, 1.91) 
  > 25 cig./day 131 0.87 (0.73, 1.05) 37 0.68 (0.49, 0.96) 31 1.13 (0.77, 1.66) 41 0.72 (0.52, 1.00) 18 1.40 (0.84, 2.35) 21 1.81 (1.11, 2.93) 
p-trend   0.04   0.01   0.41   0.006   0.19   0.01 
p-heterogeneity    0.02 0.03    
Duration of smoking                
  ≤ 10 years 10 0.78 (0.42, 1.46) 4 1.68 (0.62, 4.54) 1 -- -- 5 1.63 (0.67, 3.98) 0 -- -- 0 -- -- 
  10-19 years 24 0.91 (0.60, 1.37) 6 0.87 (0.39, 1.97) 3 1.13 (0.36, 3.56) 10 1.20 (0.64, 2.27) 1 -- -- 1 -- -- 
  20-29 years 94 0.87 (0.70, 1.09) 27 0.84 (0.56, 1.26) 15 0.86 (0.48, 1.53) 38 0.94 (0.66, 1.34) 14 1.57 (0.85, 2.89) 7 1.26 (0.55, 2.87) 
  30-39 years 401 0.90 (0.80, 1.01) 148 0.90 (0.74, 1.09) 79 1.01 (0.76, 1.33) 145 0.86 (0.70, 1.04) 41 1.18 (0.81, 1.73) 33 1.28 (0.83, 1.96) 
  ≥ 40 years 526 0.92 (0.82, 1.02) 170 0.83 (0.69, 1.00) 110 1.10 (0.86, 1.41) 138 0.75 (0.61, 0.91) 49 1.25 (0.87, 1.79) 80 1.38 (1.01, 1.87) 
p-trend   0.03   0.03   0.60   0.003   0.13   0.03 
p-heterogeneity    0.23 0.04    
 
N = number of cases 
* adjusted for height, weight, education, marital status, and vigorous physical activity 
 20 
 
Ha
za
rd
 R
at
io
 
